NTHI NeOnc Technologies Holdings Inc.

Subscribe to $NTHI

NeOnc Technologies Holdings Inc.

Subscribe to $NTHI

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

IPO Year:

Exchange: NASDAQ

Recent Analyst Ratings for NeOnc Technologies Holdings Inc.

Date	Price Target	Rating	Analyst

See more ratings

NeOnc Technologies Holdings Inc. Press Releases

Fastest customizable press release news feed in the world

View All

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

CALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the closing of its acquisition of an intellectual property portfolio featuring artificial intelligence, 3D bioprinting, and quantum modeling technologies. This move significantly fortifies NeOnc's drug discovery engine and helps accelerate its mission to develop therapies for complex neurological cancers. The newly acquired IP, which includes U.S. Patent No. 11,788,057 B2, allows NeOnc to create highly sophisticated, patient-derived 3D brain tumor model

8/25/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update

CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 19, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced financial results for the quarter ended June 30, 2025, and provided an update on recent operational achievements and upcoming milestones. Second Quarter & Recent Corporate Highlights $50 Million Strategic Partnership Secured – All contingencies finalized with Quazar Investment following incorporation of NuroMENA Holdings under Abu Dhabi Global Market (ADGM). This partnership will launch an advanced GCC & MENA clini

8/19/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

Quazar Chairman and Executive Team with NeOnc's Executive's and Directors at Quazar's Headquarters in Dubai. CALABASAS, Calif. and ABU DHABI, United Arab Emirates, Aug. 11, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, announced today the official incorporation of NuroMENA Holdings Ltd. by the Abu Dhabi Global Market (ADGM). With this regulatory milestone completed, all contingencies have now been met to finalize the previously announced $50 million cornerstone investment effort led by Quazar Investment into NuroMENA Holdings Ltd. This strateg

8/11/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

CALABASAS, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi–Phase 2 clinical-stage biotechnology company focused on breakthrough therapies for central nervous system (CNS) malignancies, today announced the award of two competitive NIH STTR (Small Business Technology Transfer) grants totaling $2.5 million. These non-dilutive funds will further advance development of the company's proprietary therapeutic compound NEO212, which is currently completing its Phase 1 clinical trial. $400,000 Phase 1 STTR Grant (1R41CA27179-01A1): Supports preclinical feasibility studies of NEO212 in acute myelogenous leukemia (AML). Dr. Thomas Chen serves as NeOn

8/7/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

CALABASAS, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, was featured on Yahoo Finance's Trader Talk with Kenny Polcari in a podcast episode titled "AI and Biotech Take on Brain Cancer." As Trader Talk describes it: "When a biotech startup lands in a major index just months after its IPO, investors take notice. In this episode of Trader Talk, Kenny Polcari speaks with Amir Heshmatpour, executive chairman and president of NeOnc Technologies (NASDAQ:NTHI), about how the company defied a tough market to go publ

8/4/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

CALABASAS, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi Phase 2 clinical-stage biotechnology company pioneering innovative treatments for brain cancers, is proud to announce the signing of a definitive, binding Letter of Intent (LOI) to acquire all outstanding equity interests in a to-be-formed Delaware entity jointly owned by Dr. Ishwar K. Puri and Beth R. Levinson. The IP portfolio, which includes U.S. Patent No. 11,788,057 B2, secured through a Patent Transfer Agreement with McMaster University, features cutting-edge 3D bioprinting, artificial intelligence, and quantum modeling technologies designed to accelerate preclinical drug dis

7/30/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment

CALABASAS, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-phase 2 clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has it has signed a definitive agreement for a $50 million strategic partnership with Quazar Investment. The definitive agreement follows NeOnc's Board unanimously approving the company's participation in the contemplated $50 million equity investment and MENA region expansion, reflecting continued momentum. "We're thrilled to take this transformative step in formalizing our strategic partnership with Quazar," said Amir Heshmatpour, E

7/29/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference

CALABASAS, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced that management will participate in the BTIG Virtual Biotechnology Conference, being held on July 29-30, 2025. Investors interested in scheduling a 1x1 meeting with management are invited to contact their BTIG representative directly or reach out to [email protected] ABOUT NEONC TECHNOLOGIES HOLDINGS, INC. NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous sys

7/28/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment

CALABASAS, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: execution and transfer of a Sub-License Agreement from NeOnc to its Abu Dhabi onshore operating subsidiary, NuroCure. The Sub-License covers the UAE and the wider GCC and MENA region with respect to NEO100 and NEO212, pursuant to NeOnc's license from USC Stevens Center for Innovation. On July 8, 2025, NeOnc announced a non-binding term sheet to

7/22/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment

CALABASAS, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a clinical-stage biotechnology company advancing transformative treatments for brain and central nervous system cancers, today announced it has achieved a key milestone toward closing its previously announced strategic transaction with Quazar Investment: formal approval from NeOnc's Board of Directors. On June 30, 2025, NeOnc's Board unanimously approved the company's participation in the contemplated $50 million equity investment and MENA region expansion under a non-binding term sheet with Quazar. This Board approval marks the first of five required milestones in the transaction c

7/10/25 9:00:00 AM ET

$NTHI

Biotechnology: Pharmaceutical Preparations

Health Care

NeOnc Technologies Holdings Inc.

Recent Analyst Ratings for NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc.

Recent Analyst Ratings for NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. Press Releases

NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board

NeOnc Technologies Holdings Reports Second Quarter 2025 Results and Provides Operational Update

NeOnc Technologies Finalizes All Contingencies for $50 Million Strategic Partnership with Quazar Investment as NuroMENA Holdings Receives ADGM Incorporation

NeOnc Technologies Awarded $2.5 Million in NIH STTR Grants to Advance NEO212 in Gliomas and Leukemia

NeOnc Technologies Featured on Yahoo Finance's Podcast Trader Talk: AI and Biotech Take on Brain Cancer

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

NeOnc Technologies Signs Definitive Agreement for $50 Million Strategic Partnership with Quazar Investment

NeOnc Technologies to Participate at the BTIG Virtual Biotechnology Conference

NeOnc Technologies Executes Sub-License Agreement, Marking Key Milestone Toward Closing $50 Million Strategic Partnership with Quazar Investment

NeOnc Technologies Secures Board Approval for $50 Million Strategic Partnership with Quazar Investment

NeOnc Technologies Holdings Inc. SEC Filings

Amendment: NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review

SEC Form 10-Q filed by NeOnc Technologies Holdings Inc.

SEC Form 8-K filed by NeOnc Technologies Holdings Inc.

SEC Form NT 10-Q filed by NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

NeOnc Technologies Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

NeOnc Technologies Holdings Inc. Insider Trading

SEC Form 3 filed by new insider Puri Ishwar Kanwar

Chief Clinical Officer Neman-Ebrahim Yousha was granted 133,000 shares (SEC Form 4)

SEC Form 3 filed by new insider Neman-Ebrahim Yousha

Amendment: Director Chiang Ming-Fu (Alan) was granted 50,000 shares, disposed of 5,994 shares, exercised 117,188 in-the-money shares at a strike of $12.00 and sold $1,433,912 worth of shares (57,696 units at $24.85), increasing direct ownership by 15% to 390,216 units (SEC Form 4)

Amendment: COO Walters Patrick disposed of 1,231 shares, exercised 24,063 in-the-money shares at a strike of $12.00 and sold $294,432 worth of shares (11,847 units at $24.85) (SEC Form 4)

Amendment: CFO Garnett Keithly disposed of 687 shares, exercised 13,438 in-the-money shares at a strike of $12.00 and sold $164,426 worth of shares (6,616 units at $24.85) (SEC Form 4)

Amendment: Director Heshmatpour Amir F disposed of 3,996 shares, exercised 78,125 in-the-money shares at a strike of $12.00 and sold $955,941 worth of shares (38,464 units at $24.85) (SEC Form 4)

Amendment: CEO Chen Thomas C disposed of 4,076 shares, exercised 79,688 in-the-money shares at a strike of $12.00 and sold $975,055 worth of shares (39,233 units at $24.85) (SEC Form 4)

President Heshmatpour Amir F bought $14,785 worth of CommonStock (2,000 units at $7.39), increasing direct ownership by 0.11% to 1,762,000 units (SEC Form 4)

CEO Chen Thomas C bought $40,002 worth of shares (5,468 units at $7.32), increasing direct ownership by 1% to 551,668 units (SEC Form 4)

NeOnc Technologies Holdings Inc. Insider Purchases

President Heshmatpour Amir F bought $14,785 worth of CommonStock (2,000 units at $7.39), increasing direct ownership by 0.11% to 1,762,000 units (SEC Form 4)

CEO Chen Thomas C bought $40,002 worth of shares (5,468 units at $7.32), increasing direct ownership by 1% to 551,668 units (SEC Form 4)

CFO Garnett Keithly bought $4,921 worth of shares (675 units at $7.29), increasing direct ownership by 0.28% to 240,900 units (SEC Form 4)

CFO Garnett Keithly bought $976 worth of shares (135 units at $7.23), increasing direct ownership by 0.06% to 240,225 units (SEC Form 4)

Amendment: CFO Garnett Keithly bought $631 worth of shares (90 units at $7.01), increasing direct ownership by 0.04% to 240,090 units (SEC Form 4)

Director Delshad Jim bought $37,258 worth of shares (5,100 units at $7.31), increasing direct ownership by 10% to 55,310 units (SEC Form 4)

CFO Garnett Keithly decreased direct ownership by 0.03% to 330,000 units (SEC Form 4)

CEO Chen Thomas C bought $2,800 worth of shares (400 units at $7.00), increasing direct ownership by 0.07% to 546,200 units (SEC Form 4)

President Heshmatpour Amir F bought $47,294 worth of shares (6,490 units at $7.29) and bought $59,221 worth of CommonStock (3,510 units at $16.87), increasing direct ownership by 0.57% to 1,760,000 units (SEC Form 4)

NeOnc Technologies Holdings Inc. Leadership Updates

NeOnc Technologies Signs Definitive Agreement to Acquire AI, 3D, and Quantum Modeling IP Portfolio from Dr. Ishwar K. Puri; Appoints Him to Board of Directors

NeOnc Technologies Holdings, Inc. Appoints Dr. Josh Neman as Chief Clinical Officer to Advance Clinical Strategy and Translational Oncology Programs